These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 16203821

  • 21. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer.
    Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ, Bander NH, Nanus DM.
    Cancer; 2019 Aug 01; 125(15):2561-2569. PubMed ID: 31012963
    [Abstract] [Full Text] [Related]

  • 22. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
    Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, Russell CD, Liu T, Grizzle WE, Schlom J, LoBuglio AF, Meredith RF.
    Gynecol Oncol; 1997 Apr 01; 65(1):94-101. PubMed ID: 9103398
    [Abstract] [Full Text] [Related]

  • 23. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G.
    Clin Cancer Res; 1995 Dec 01; 1(12):1447-54. PubMed ID: 9815943
    [Abstract] [Full Text] [Related]

  • 24. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
    Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD.
    Cancer Biother Radiopharm; 1999 Apr 01; 14(2):99-111. PubMed ID: 10850293
    [Abstract] [Full Text] [Related]

  • 25. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
    Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.
    Nucl Med Biol; 2006 Nov 01; 33(8):1065-72. PubMed ID: 17127181
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.
    Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH.
    Cancer; 2010 Feb 15; 116(4 Suppl):1075-83. PubMed ID: 20127956
    [Abstract] [Full Text] [Related]

  • 31. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
    Michel RB, Andrews PM, Rosario AV, Goldenberg DM, Mattes MJ.
    Nucl Med Biol; 2005 Apr 15; 32(3):269-78. PubMed ID: 15820762
    [Abstract] [Full Text] [Related]

  • 32. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera DA, Brechbiel MW, Burns LJ, Panoskaltsis-Mortari A, Dusenbery KE, Clohisy DR, Vitetta ES.
    Clin Cancer Res; 2005 Nov 01; 11(21):7920-8. PubMed ID: 16278417
    [Abstract] [Full Text] [Related]

  • 33. Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE, Ohlsson T, Nilsson R, Tennvall J.
    Cancer Biother Radiopharm; 2012 Mar 01; 27(2):134-40. PubMed ID: 22229635
    [Abstract] [Full Text] [Related]

  • 34. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
    Muselaers CH, Oosterwijk E, Bos DL, Oyen WJ, Mulders PF, Boerman OC.
    Mol Imaging; 2014 Mar 01; 13():1-7. PubMed ID: 24824962
    [Abstract] [Full Text] [Related]

  • 35. Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate.
    Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D, Miller LS, Houchens D, Cheng R, Kaplan D, Goeckeler W.
    Cancer Res; 1991 Jun 01; 51(11):2889-96. PubMed ID: 1851665
    [Abstract] [Full Text] [Related]

  • 36. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
    Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I, Wiesneth M, Kotzerke J, Zenz T, Buck AK, Schauwecker P, Stilgenbauer S, Döhner H, Reske SN, Bunjes D.
    Br J Haematol; 2005 Aug 01; 130(4):604-13. PubMed ID: 16098076
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Specific radioimmunotherapy using 90Y-labeled monoclonal antibody in erythroleukemic mice.
    Anderson-Berg WT, Squire RA, Strand M.
    Cancer Res; 1987 Apr 01; 47(7):1905-12. PubMed ID: 3469024
    [Abstract] [Full Text] [Related]

  • 40. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.
    Clin Cancer Res; 2002 Sep 01; 8(9):2806-11. PubMed ID: 12231520
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.